This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.


Uniting Antibodies and Cell Therapy to Fight Cancer

Acepodia is developing potent, off-the-shelf targeted cancer cell therapies that unlock the immune system’s ability to fight both solid tumors and hematological malignancies.

Antibody-Cell Conjugation (ACC), is inherited from Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry which moves click chemistry into living organisms. And she won the Nobel Prize for Chemistry in 2022. ACC technology uses this live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to dramatically enhance the ability of oNK cells and γδ2 T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-γδ2 T and oNK therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.

Applying The ACC Approach
Highly Versatile and Broadly Applicable

Highly Versatile and Broadly Applicable

In addition to the benefits of potency conferred by ACC, its simplicity and modular “plug and play” nature could make cell therapies more accessible to patients and allows for the expansion into other indications beyond oncology and other immune cells.
High Affinity and Selectivity

High Affinity and Selectivity

The antibody-cell conjugation(ACC) can be divided into three elements. The click chemistry is involved in the conjugation process that clicks antibodies to the live cells. And the aptamer we use in ACC is functional as a T cell engager, one arm engages with T cell and the other arm can selectively grab tumor cell which subsequently enhances potency through immune activation receptors activating NFAT signaling pathway. The covalent bonding of aptamer sustains the high affinity of antibody-conjugated effector cells toward the tumor cells.
In the Clinic: ACC candidate for solid tumors and hematological malignancies

In the Clinic: ACC candidate for solid tumors and hematological malignancies

Acepodia’s lead clinical candidates are ACE1831(CD20-targeting ACC- gamma delta2 (γδ2) T cell therapy) and ACE1702 (HER2-targeting ACC-oNK cell therapy). ACE1702 is developed for the treatment of HER2-expressing solid tumors. ACE1831 is developed for the treatment of relapsed / refractory non-Hodgkin’s lymphoma.

Potent, Off-the-Shelf Cell Lines as the Chassis for our ACC Technology

In order to develop the most effective immunotherapies possible, Acepodia equips its ACC technology to both of its proprietary gamma delta2 (γδ2) T cells and off-the-shelf NK (oNK) cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody, new or existing, to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to our already potent and off-the-shelf biologic drug payloads.




Phase I
Phase II
CD20 Targeting, ACC-γδ2 T Cell Therapy
Phase I ​
EGFR Targeting, ACC-γδ2 T Cell Therapy
Preclinical ​
PD-L1 Targeting, ACC-γδ2 T Cell Therapy
Preclinical ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.